Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients

• Status: Terminated
• Trial end date: 2020-04-24
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this prospective randomized double blinded placebo controlled study is to investigate if a single dose of ketamine in addition to standard anesthesia will reduce the risk of delirium in otolaryngeal cancer patients postoperatively. Ketamine's effect on post-operative pain and opioid use will be measured as well. Electroencephalogram (EEG) will be utilized during the surgical procedure to evaluate its potential as a possible predictive device for delirium.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Current diagnosis of otolaryngeal cancer and undergoing surgery with general anesthesia

• Competent to provide informed consent

Exclusion Criteria:

• Emergency surgery

• Monitored Anesthesia Care (i.e., regional anesthesia alone without plans for general anesthesia)

• Surgery involving the eye, eyebrow, forehead, or frontal scalp near the sensor placement

• Poor health literacy

• Allergy, or have experienced any drug reaction to ketamine

• Pregnant or lactating

• Currently in active alcohol withdrawal

• Taking buprenorphine for chronic pain